查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018791

前列腺癌核醫診斷市場：按放射性藥物、檢測方法、適應症和最終用戶分類－2026年至2032年全球市場預測

Prostate Cancer Nuclear Medicine Diagnostics Market by Radiopharmaceutical, Modality, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，攝護腺癌核醫診斷市場價值將達到 13.1 億美元，到 2026 年將成長至 14.9 億美元，到 2032 年將達到 31.2 億美元，年複合成長率為 13.17%。

主要市場統計數據
基準年 2025 13.1億美元
預計年份：2026年 14.9億美元
預測年份 2032 31.2億美元
複合年成長率 (%) 13.17%

對臨床、技術和商業性因素在重塑前列腺癌治療中的核醫學診斷方面的整合持謹慎觀點。

受分子影像技術的進步、臨床路徑的演變以及跨學科合作的加強推動，前列腺癌核醫學診斷的臨床和技術格局正在經歷重大變化。過去的傳統影像學方法依賴常規技術，而如今，更靈敏的放射性藥物和混合影像平台正被應用於診斷實踐，從而能夠更準確地識別病灶、進行分期和檢測復發。因此，臨床醫生和醫療系統正在重新評估診斷流程，以最佳化患者分層和治療決策。

本檢驗了一個關鍵的技術和臨床轉折點，該轉折點正在提高前列腺癌診斷的準確性，並重新定義基於影像的診斷路徑。

近年來，攝護腺癌核醫領域發生了變革性變化，正在改變診斷流程和相關人員預期。針對前列腺特異性膜抗原（PSMA）藥物的成熟拓寬了臨床醫師的選擇範圍，提高了早期病灶的檢出率，並促使人們重新評估影像學標準。放射化學的同步發展使得<sup>18</sup>F標記藥物相比基於發生器的同位素具有諸多優勢，而新型同位素的出現則進一步拓展了診斷和潛在的治療診斷學（治療與診斷相結合）工具箱。

新的貿易措施將如何促進核醫診斷領域的策略供應鏈調整、生產地理多元化和採購創新。

貿易當局推出的新關稅措施對支撐核子醫學診斷的複雜全球供應鏈產生了重大影響。對關鍵組件、試劑和成品放射性藥物徵收的關稅將影響製造商、放射性藥物藥房和診斷影像中心的採購決策。隨著進口關稅的提高，各機構面臨更高的接收成本，並被迫重新評估籌資策略，以維持服務的連續性和競爭優勢。

將放射性藥物選擇、影像方式功能、醫療保健服務環境屬性和臨床適應症與可操作的診斷策略聯繫起來的詳細細分見解。

基於細分市場的洞察揭示了放射性藥物類別、影像方式、醫療服務環境和臨床適應症的不同趨勢，有助於制定部署策略。基於放射性藥物，本研究對<sup>11</sup>C膽鹼、<sup>18</sup>F DcfpyL、<sup>18</sup>F氟環己烷、<sup>68</sup>Ga PSMA以及新興藥物進行了市場分析，其中對<sup>18</sup>F PSMA 1007和Cusup>64</sup>64</sup>這兩種新興藥物更詳細的分析。每類藥物都具有獨特的生產、物流和臨床部署特徵，這些特徵會影響部署地點和方法。基於影像方式，市場分為PET和SPECT，PET又細分為數位PET和飛行時間PET，SPECT則分為傳統SPECT和SPECT-CT。這些區分突顯了不同機構必須權衡的解析度、處理能力和資本投資需求。按最終用戶分類，本研究針對學術研究機構、診斷中心和醫院進行了市場分析。這種細分突顯了營運規模、臨床複雜性和院內放射化學資源取得的差異，這些差異會影響部署計畫。基於適應症的分析檢視了生化復發檢測、早期分期和治療監測的市場。針對這些適應症選擇合適的藥物和方法，可以最大限度地提高診斷準確性和臨床效用。

從區域觀點分析影響全球先進核醫診斷技術取得和應用的法規、基礎設施和支付方。

區域趨勢受法規環境、基礎設施建設和支付框架差異的影響，這些因素對先進核醫學診斷技術的採用和推廣有顯著影響。在美洲，臨床應用主要得益於優秀的醫療中心、完善的放射性藥物分發網路以及對影像結果與治療決策之間關聯證據的日益重視。因此，早期應用往往集中在大學醫院和專科癌症中心附近。在歐洲、中東和非洲，情況則各不相同，一些國家正在迅速採用先進的PET放射性藥物和尖端掃描儀技術，而另一些國家則由於基礎設施和報銷體系的差異而面臨應用受限的問題。區域中心與國家醫療體系之間的協調在擴大應用範圍方面發揮著至關重要的作用。在亞太地區，由於對影像基礎設施的大力投資、訓練有素的專業人員數量的增加以及戰略性行業合作，技術應用正在加速發展，但放射性藥物分發方面的物流挑戰和監管協調仍然是需要優先考慮的問題。

開發商、設備供應商、放射性藥物藥局和臨床中心之間進行策略性競爭與合作，以推動臨床檢驗和市場准入。

核子醫學診斷領域的競爭動態呈現出放射性藥物研發公司、影像設備製造商、商業放射性藥物供應機構和學術研究聯盟等多種參與者並存的局面。放射性藥物研發公司正積極投資臨床試驗並擴大生產規模，以確保臨床應用；而影像系統供應商則專注於硬體和軟體創新，以提高靈敏度和易用性。商業放射性藥物供應機構和第三方迴旋加速器營運商的重要性日益凸顯，因為它們提供的分散式生產解決方案降低了不具備自身生產能力的醫療機構的進入門檻。

為領導者制定優先行動指南，透過協調證據產生、供應鏈韌性、支付方合作和營運準備來加快招募速度。

致力於利用核子醫學進展治療前列腺癌的行業領導者應採取一致的策略，將臨床證據的累積、供應鏈的韌性以及與支付方的合作有機結合起來。首先，應優先進行以決策終點為導向的臨床研究，例如影像學檢查如何影響治療策略和患者預後。這些數據對於確定保險報銷和納入臨床指南至關重要。其次，應投資於靈活的生產和分銷模式，包括與當地迴旋加速器營運商和商業放射性藥物分銷商建立合作關係，以降低貿易和物流中斷的風險。

為了確保獲得可靠的見解，我們採用透明、多方面的研究途徑，結合與專家的初步訪談、同儕審查證據的整合以及迭代檢驗。

支持這些發現的研究結合了基於證據的同行評審文獻、監管指南和公開的臨床試驗註冊信息，以及對臨床、生產和商業領域專家的結構化訪談。主要研究包括與核子醫學專家、放射性藥物藥劑師和影像科主任進行定性討論，以了解實際工作流程中的考慮因素、實施障礙和技術性能權衡。次要研究整合了技術白皮書、共識指南和產品文檔，以闡明成像方式的功能和藥物特性。

本文簡要概述了技術創新、營運韌性和實證商業化將如何融合，從而塑造前列腺癌診斷的未來。

放射性藥物、影像設備和分析技術的進步正在全面提升核醫診斷在前列腺癌治療中的作用。這些進展能夠更精準地檢測病灶，改善臨床決策，並為診斷和治療計劃的更緊密結合鋪平道路。同時，貿易政策的變化和日益複雜的供應鏈凸顯了戰略韌性和本土化能力的重要性。因此，一個快速發展的生態系統正在形成，在這個系統中，技術創新需要切實可行的商業化策略、證據生成以及與保險公司的合作。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：攝護腺癌核醫診斷市場－以放射性藥物分類

  • 11C 科林
  • 18F-DCFPyL
  • 18F 全環蛋白
  • 68Ga-PSMA
  • 新興藥物
    • 18F-PSMA-1007
    • 64Cu-PSMA

第9章：攝護腺癌核醫診斷市場：依模式分類

  • PET
    • 數字PET
    • 飛行時間PET
  • SPECT
    • 常規SPECT
    • SPECT-CT

第10章：攝護腺癌核子醫學診斷市場：依適應症分類

  • 生化復發檢測
  • 早期分類
  • 治療監測

第11章：攝護腺癌核醫診斷市場：依最終用戶分類

  • 學術研究機構
  • 診斷中心
  • 醫院

第12章：攝護腺癌核醫診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：攝護腺癌核醫診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：前列腺癌核醫診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國攝護腺癌核醫診斷市場

第16章：中國前列腺癌症核醫學診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ABX Advanced Biochemical Compounds GmbH
  • Bayer AG
  • Blue Earth Diagnostics Inc.
  • Bracco Imaging SpA
  • Cardinal Health, Inc.
  • Curium Pharma
  • Eckert & Ziegler Strahlen-und Medizintechnik AG
  • GE HealthCare Technologies Inc.
  • Isotope Technologies Munich SE
  • Jubilant Radiopharma
  • Koninklijke Philips NV
  • Lantheus Holdings, Inc.
  • NCM-USA LLC
  • Novartis AG
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited
Product Code: MRR-ED54C46E821C

The Prostate Cancer Nuclear Medicine Diagnostics Market was valued at USD 1.31 billion in 2025 and is projected to grow to USD 1.49 billion in 2026, with a CAGR of 13.17%, reaching USD 3.12 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.31 billion
Estimated Year [2026] USD 1.49 billion
Forecast Year [2032] USD 3.12 billion
CAGR (%) 13.17%

A thoughtful orientation to the converging clinical, technical, and commercial forces reshaping nuclear medicine diagnostics for prostate cancer care

The clinical and technological landscape of nuclear medicine diagnostics for prostate cancer is undergoing a significant transformation driven by advances in molecular imaging, evolving clinical pathways, and increasing interdisciplinary collaboration. Historically anchored in conventional imaging modalities, diagnostic practice now incorporates higher-sensitivity radiopharmaceuticals and hybrid imaging platforms that deliver more precise localization, staging, and recurrence detection. As a result, clinicians and health systems are re-evaluating diagnostic algorithms to optimize patient stratification and therapeutic decision-making.

Alongside clinical adoption, investments in imaging infrastructure, radiochemistry capabilities, and workforce training are reshaping operational considerations for providers. Radiopharmaceutical innovation is complemented by improvements in scanner hardware and software that enhance image quality and throughput, enabling more reliable detection of small-volume disease. Simultaneously, stakeholders across biopharma, device manufacturing, and academic centers are generating evidence on clinical utility and health outcomes, which in turn informs payer dialogues and pathway integration.

Looking forward, the interplay between regulatory frameworks, reimbursement policies, and supply chain resilience will determine how rapidly these innovations translate into routine care. Strategic partnerships and data-driven approaches are becoming essential for organizations that aim to influence clinical practice and capture value. In this context, understanding the technical, clinical, and commercial vectors that drive adoption is critical for executives, clinicians, and investors seeking to navigate the next phase of nuclear medicine diagnostics for prostate cancer.

An examination of the pivotal technological and clinical inflection points that are accelerating diagnostic precision and redefining imaging pathways for prostate cancer

Recent years have seen transformative shifts in prostate cancer nuclear medicine that are altering diagnostic pathways and stakeholder expectations. The maturation of prostate-specific membrane antigen-targeted agents has expanded options for clinicians, improving lesion detection at lower disease burdens and prompting reappraisal of imaging indications. Parallel advances in radiochemistry have enabled 18F-labeled agents to offer logistical advantages over generator-based isotopes, while the emergence of novel isotopes broadens the diagnostic and potential theranostic toolkit.

Concurrently, imaging hardware and analytical platforms have progressed. Time-of-flight and digital PET capabilities deliver higher spatial resolution and sensitivity, which not only improve diagnostic confidence but also reduce scan durations and dose requirements. Hybrid SPECT/CT remains relevant for specific indications, yet the overall momentum favors PET-centric workflows where clinical evidence supports incremental diagnostic yield. Integration of quantitative imaging metrics and AI-enabled post-processing is beginning to standardize reporting and reduce inter-reader variability, thereby strengthening the link between imaging outputs and management decisions.

In the policy and commercial arenas, reimbursement pathways are evolving in response to accumulating clinical evidence, though variability persists across payers and geographies. Supply chain considerations have risen to prominence as manufacturers, radiopharmacies, and providers respond to logistics, cold-chain management, and production scalability. Taken together, these shifts reflect a broader movement toward precision diagnostics that align imaging modality, agent selection, and clinical intent to yield actionable information for personalized prostate cancer care.

How new trade measures are prompting strategic supply chain adaptation, production regionalization, and procurement innovation across nuclear medicine diagnostics

The introduction of new tariff measures by trade authorities has material implications for the complex, global supply chains that underpin nuclear medicine diagnostics. Tariffs applied to key components, reagents, and finished radiopharmaceuticals influence procurement decisions across manufacturers, radiopharmacies, and imaging centers. When import duties rise, organizations confront higher landed costs and the need to reassess sourcing strategies to preserve service continuity and competitive positioning.

In response to tariff-driven cost pressures, companies and health systems are likely to pursue greater regionalization of production and strengthened local partnerships. Investments in domestic radiochemistry capacity and regional distribution networks become more attractive as a hedge against trade friction. Moreover, manufacturers may accelerate efforts to qualify alternative isotopes or labeling chemistries that can be produced locally or that rely less on tariff-affected inputs. Such adaptations help mitigate exposure but require capital, lead time, and regulatory coordination.

Operationally, imaging providers must navigate a mix of procurement, inventory, and contractual adjustments. Longer-term contracts, diversified supplier bases, and closer alignment with academic centers or third-party cyclotron operators can reduce vulnerability to cost volatility. From a strategic standpoint, trade-related cost shifts also influence cost-effectiveness assessments and payer negotiations, particularly where higher acquisition costs are not matched by demonstrable reductions in downstream expenditures. Ultimately, tariffs act as a catalyst for supply chain reconfiguration, encouraging resilience-building measures while placing a premium on coordination across commercial, clinical, and regulatory stakeholders.

Granular segmentation insights that connect radiopharmaceutical selection, imaging modality capabilities, care setting attributes, and clinical indication to actionable diagnostic strategies

Segmentation-based insights reveal differentiated dynamics across radiopharmaceutical categories, imaging modalities, care settings, and clinical indications that inform deployment strategies. Based on Radiopharmaceutical, the market is studied across 11C Choline, 18F DcfpyL, 18F Fluciclovine, 68Ga PSMA, and Emerging Agents, with the Emerging Agents further examined across 18F PSMA 1007 and 64Cu PSMA; each agent class exhibits unique production, logistical, and clinical adoption characteristics that affect where and how they are implemented. Based on Modality, the market is studied across PET and SPECT, with PET further divided into Digital PET and Time Of Flight PET and SPECT subdivided into Conventional SPECT and SPECT CT; these distinctions highlight trade-offs between resolution, throughput, and capital requirements that facilities must weigh. Based on End User, the market is studied across Academic Research Institutes, Diagnostic Centers, and Hospitals; this segmentation underscores differences in operational scale, clinical complexity, and access to on-site radiochemistry that shape adoption timelines. Based on Indication, the market is studied across Biochemical Recurrence Detection, Initial Staging, and Treatment Monitoring; aligning agent and modality selection to these indications maximizes diagnostic yield and clinical utility.

Understanding how these segments intersect is essential. For example, highly sensitive PET agents paired with digital PET scanners can be particularly impactful in settings focused on biochemical recurrence detection, but such pairings require investment in imaging infrastructure and reliable radiopharmaceutical supply. Conversely, hospitals with integrated oncology services may prioritize agents and modalities that support both staging and treatment monitoring workflows, leveraging in-house radiochemistry or strategic supplier agreements. Academic research institutes play a pivotal role in validating emerging agents and refining clinical protocols, thereby influencing downstream adoption across diagnostic centers and hospitals. By mapping clinical questions to the right combination of agent, modality, and care setting, stakeholders can optimize diagnostic pathways and resource allocation.

Region-specific perspectives on regulatory, infrastructural, and payer drivers that shape access and adoption of advanced nuclear medicine diagnostics globally

Regional dynamics exert a strong influence on the adoption and diffusion of advanced nuclear medicine diagnostics, shaped by differences in regulatory environments, infrastructure capacity, and payer frameworks. In the Americas, clinical uptake has been driven by centers of excellence, an established radiopharmacy network, and a growing emphasis on evidence that links imaging outcomes to therapeutic decision-making; consequently, early adoption clusters often emerge around academic hospitals and specialized cancer centers. Across Europe, Middle East & Africa, the landscape is heterogeneous, with some countries showing rapid integration of advanced PET agents and modern scanner technologies while others face constrained access due to infrastructure or reimbursement variability; collaboration between regional hubs and national health systems plays an important role in expanding access. In the Asia-Pacific region, strong investments in imaging infrastructure, increasing numbers of trained specialists, and strategic industrial partnerships are accelerating adoption, though logistical considerations for radiopharmaceutical distribution and regulatory harmonization remain ongoing priorities.

Transitioning from regional observation to action, stakeholders should consider the unique enablers and constraints of each geography when planning commercialization and access strategies. Supply chain design, regulatory engagement, and payer evidence-generation must be tailored to regional realities. Moreover, leveraging regional centers of clinical excellence to demonstrate value and disseminate best practices can expedite more equitable access and consistent standards of care across diverse healthcare systems.

Strategic competitive and collaborative behaviors among developers, equipment vendors, radiopharmacies, and clinical centers that drive clinical validation and market access

Competitive dynamics within the nuclear medicine diagnostics space reflect a blend of specialized radiopharmaceutical developers, imaging equipment manufacturers, commercial radiopharmacies, and academic research consortia. Radiopharmaceutical developers are investing in clinical trials and manufacturing scale-up to secure clinical uptake, while imaging systems vendors focus on hardware and software innovations that improve sensitivity and usability. Commercial radiopharmacies and third-party cyclotron operators are increasingly important as they provide distributed production solutions that lower barriers to entry for clinics without on-site manufacturing capacity.

Collaborations and strategic alliances are central to advancing both clinical evidence and market access. Developers often partner with academic centers to validate clinical endpoints and with imaging vendors to optimize agent-scanner compatibility. Meanwhile, diagnostic centers and hospitals form pilot programs to demonstrate workflow integration, cost implications, and patient outcomes. Regulatory strategy and payer engagement remain differentiating activities: organizations that proactively generate robust comparative and health outcomes evidence are better positioned to negotiate coverage and embed their technologies into clinical pathways. From a commercial perspective, companies that offer bundled solutions-combining agent supply, imaging systems, and service support-can simplify adoption for providers and create stickier customer relationships.

A prioritized playbook for leaders that aligns evidence generation, supply chain resilience, payer engagement, and operational readiness to accelerate adoption

Industry leaders seeking to capitalize on advances in prostate cancer nuclear medicine should pursue a coherent strategy that aligns clinical evidence generation, supply chain resilience, and payer engagement. First, prioritize clinical studies that address decision-impact endpoints, such as how imaging alters management pathways and downstream patient outcomes; these data are the currency that informs reimbursement and guideline inclusion. Second, invest in flexible manufacturing and distribution models, including partnerships with regional cyclotron operators and commercial radiopharmacies, to reduce exposure to trade and logistical disruption.

In parallel, accelerate adoption of advanced imaging hardware and analytics where clinical benefit is established, but pair capital investment with operational training programs to ensure efficient utilization. Engage proactively with payers and health technology assessment bodies by presenting pragmatic evidence packages and health-economic narratives that reflect real-world workflows. Foster strategic alliances across the value chain-linking developers, imaging vendors, providers, and patient advocacy groups-to create integrated value propositions that lower adoption friction. Finally, embed digital data strategies that enable longitudinal outcome tracking and real-world evidence generation; such capabilities support continuous improvement, regulatory interactions, and commercialization efforts. Together, these measures create a durable foundation for clinical impact and sustainable commercial performance.

A transparent, multi-source research approach combining primary expert interviews, peer-reviewed evidence synthesis, and iterative validation to ensure robust insights

The research underpinning these insights combined an evidence-based review of peer-reviewed literature, regulatory guidance, and publicly available clinical trial registries with structured interviews of domain experts across clinical, manufacturing, and commercial functions. Primary research included qualitative discussions with practicing nuclear medicine physicians, radiopharmacists, and imaging operations leads to capture real-world workflow considerations, adoption barriers, and technology performance trade-offs. Secondary research synthesized technical white papers, consensus guidelines, and product documentation to characterize modality capabilities and agent properties.

Findings were validated through triangulation across multiple sources and refined by iterative consultation with methodologists and subject matter experts. Data quality control measures included source cross-checking, reconciliation of conflicting inputs, and a focus on clinical utility endpoints rather than proprietary commercial metrics. The research approach prioritized transparency in methodology and reproducibility of findings to support robust decision-making by clinical leaders, manufacturers, and policymakers. Where gaps in evidence existed, the analysis identified research priorities and recommended study designs to close those gaps efficiently.

A concise synthesis of how technological innovation, operational resilience, and evidence-driven commercialization converge to shape future prostate cancer diagnostics

Advances in radiopharmaceuticals, imaging hardware, and analytic technologies are collectively elevating the role of nuclear medicine diagnostics in prostate cancer care. These developments enable more precise lesion detection, improve clinical decision-making, and open pathways for closer integration of diagnostics with therapeutic planning. At the same time, trade policy shifts and supply chain complexities underscore the need for strategic resilience and localized capabilities. The net effect is a rapidly evolving ecosystem in which technical innovation must be matched by pragmatic commercialization strategies, evidence generation, and payer engagement.

For stakeholders across the value chain, the imperative is clear: align clinical priorities with operational realities and market access strategies. By investing in robust clinical validation, securing diversified and resilient supply chains, and articulating clear value propositions to payers and providers, organizations can accelerate the translation of diagnostic innovation into improved patient outcomes. Collaboration and data-sharing across institutions will further amplify the pace of adoption and the consistency of care. Ultimately, thoughtful execution across clinical, commercial, and logistical domains will determine which innovations achieve meaningful, sustained impact in prostate cancer diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prostate Cancer Nuclear Medicine Diagnostics Market, by Radiopharmaceutical

  • 8.1. 11C Choline
  • 8.2. 18F DcfpyL
  • 8.3. 18F Fluciclovine
  • 8.4. 68Ga Psma
  • 8.5. Emerging Agents
    • 8.5.1. 18F Psma 1007
    • 8.5.2. 64Cu Psma

9. Prostate Cancer Nuclear Medicine Diagnostics Market, by Modality

  • 9.1. Pet
    • 9.1.1. Digital Pet
    • 9.1.2. Time Of Flight Pet
  • 9.2. Spect
    • 9.2.1. Conventional Spect
    • 9.2.2. Spect Ct

10. Prostate Cancer Nuclear Medicine Diagnostics Market, by Indication

  • 10.1. Biochemical Recurrence Detection
  • 10.2. Initial Staging
  • 10.3. Treatment Monitoring

11. Prostate Cancer Nuclear Medicine Diagnostics Market, by End User

  • 11.1. Academic Research Institute
  • 11.2. Diagnostic Center
  • 11.3. Hospital

12. Prostate Cancer Nuclear Medicine Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Prostate Cancer Nuclear Medicine Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Prostate Cancer Nuclear Medicine Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Prostate Cancer Nuclear Medicine Diagnostics Market

16. China Prostate Cancer Nuclear Medicine Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. ABX Advanced Biochemical Compounds GmbH
  • 17.6. Bayer AG
  • 17.7. Blue Earth Diagnostics Inc.
  • 17.8. Bracco Imaging S.p.A.
  • 17.9. Cardinal Health, Inc.
  • 17.10. Curium Pharma
  • 17.11. Eckert & Ziegler Strahlen- und Medizintechnik AG
  • 17.12. GE HealthCare Technologies Inc.
  • 17.13. Isotope Technologies Munich SE
  • 17.14. Jubilant Radiopharma
  • 17.15. Koninklijke Philips N.V.
  • 17.16. Lantheus Holdings, Inc.
  • 17.17. NCM-USA LLC
  • 17.18. Novartis AG
  • 17.19. Siemens Healthineers AG
  • 17.20. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 142. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 143. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 145. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 146. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 166. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 169. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 170. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 174. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 175. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 177. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 178. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)